Phase 1 Clinical Study of JTE-052A - Single and Multiple Dose study -

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222444

Enrollment

Registered

2014-03-28

Start date

2014-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers and skin diseases

Interventions

investigational material(s) Generic name etc : JTE-052A INN of investigational material : delgocitinib Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Healthy volunteers -Patients with skin diseases

Exclusion criteria

Exclusion criteria: Part1 - Those who have a history of contact dermatitis caused by dermatological drugs, tape, adhesive plaster, compression, etc. or mechanical urticaria Part2, Part3 - Those who have a history of contact dermatitis caused by dermatological drugs, tape, adhesive plaster, compression, etc. or mechanical urticaria - Those who have changed the dosage regimen of topical steroids or tacrolimus hydrate ointment within 7 days before the day of spitalization

Design outcomes

Primary

Measure	Time frame
safety Adverse Events	—

Secondary

Measure	Time frame
pharmacokinetics Study drug concentraion in plasma	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026